Last reviewed · How we verify

Spikevax Omicron XBB.1.5

Jules Bordet Institute · FDA-approved active Biologic

Spikevax Omicron XBB.1.5 is an mRNA vaccine that instructs cells to produce the spike protein of the XBB.1.5 Omicron variant of SARS-CoV-2, triggering an immune response to protect against COVID-19 infection.

Spikevax Omicron XBB.1.5 is an mRNA vaccine that instructs cells to produce the spike protein of the XBB.1.5 Omicron variant of SARS-CoV-2, triggering an immune response to protect against COVID-19 infection. Used for COVID-19 prevention in adults (booster dose).

At a glance

Generic nameSpikevax Omicron XBB.1.5
SponsorJules Bordet Institute
Drug classmRNA vaccine
TargetSARS-CoV-2 spike protein (XBB.1.5 variant)
ModalityBiologic
Therapeutic areaImmunology / Infectious Disease
PhaseFDA-approved

Mechanism of action

The vaccine contains lipid nanoparticles encapsulating mRNA encoding the spike protein of the XBB.1.5 Omicron subvariant. Upon intramuscular injection, the mRNA is translated by host cells to produce spike protein antigen, which stimulates both humoral (antibody) and cellular (T-cell) immune responses. This updated formulation targets circulating Omicron subvariants to enhance protection against current variants of concern.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: